Implantable pump could ease diabetes management for 40 patients
NCT ID NCT06739811
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times
Summary
This study is testing a new implantable insulin pump (MIIPS 2020) in 40 adults with type 1 diabetes whose blood sugar is hard to control with standard insulin shots or external pumps. The pump is placed inside the body and delivers insulin directly, aiming to reduce dangerous high and low blood sugar episodes. The main goal is to see how accurately the pump delivers insulin over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subject is aged ≥ 18 years old. 2. Subject has a clinical diagnosis of type 1 diabetes for ≥ 6 months prior to screening as determined via medical record or source documentation by an individual qualified to make a medical diagnosis. 3. Subject with type 1 diabetes mellitus that cannot be controlled with subcutaneous insulin therapy (including external pump), presenting with frequent, otherwise unexplained severe hyper-and/or hypoglycaemia. 4. Subject has access to a reliable support person, defined as an individual who has daily contact with the subject and knows who to contact in the event of an emergency (i.e., caregiver). 5. Subject has the physical and intellectual ability (in the opinion of the study investigator) to operate the MIIP system and to comply with the data reporting requirements of the study. 6. Subject is willing and able to sign and date informed consent, comply with all study procedures as required during the study. Exclusion Criteria: 1. Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or device before enrollment into this study, that could impact the outcomes of this study; as per investigator and sponsor judgment. 2. Subject has any other disease or condition that may increase risks during the implant procedure or may preclude the subject from participating in the study, as determined by a physician who is not the principal investigator. 3. Subject has any known or suspected allergy to insulin or implantable materials of the MIIPS (pump and catheter) as determined by a physician. 4. Subject is a woman who is pregnant, or of childbearing potential, or lactating, and who is neither surgically sterile, nor using contraceptives (devices, oral, implanted or other physician-approved contraceptive), or willing to use them, at the time of enrollment. 5. Subject is vulnerable, legally incompetent or illiterate. 6. Residence or planned non-pressurized travel at elevations above 10000 feet/3048 meters (commercial airline travel is acceptable). 7. Planning to engage in activities requiring a descent greater than or equal to 10 feet/3 meters below sea level. 8. Subject has an active infection requiring antibiotic treatment. 9. Subject is a person whose body size is not sufficient to accept implantable pump bulk and weight. 10. Subject has a life expectancy of less than 9 months. 11. Subject has diagnosis of illicit drugs abuse disorder. 12. Subject has diagnosis of marijuana abuse disorder. 13. Subject has diagnosis of prescription drugs abuse disorder. 14. Subject has diagnosis of alcohol abuse disorder. 15. Subject who is unwilling or unable to monitor their glucose level or wear a personal continuous glucose monitor. 16. Subject who is unwilling or unable to make programming modifications to the pump based on glucose level readings.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type I diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
11 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Dijon Bourgogne
RECRUITINGDijon, 21100, France
-
CHU Lille - Hôpital Huriez
NOT_YET_RECRUITINGLille, France, 59037, France
-
CHU de Nancy - Hôpital d'Adultes de Brabois
NOT_YET_RECRUITINGNancy, France, 54511, France
-
CHU de Toulouse - Hôpital Rangueil
RECRUITINGToulouse, France, 31059, France
-
Centre Hospitalier Sud Francilien
NOT_YET_RECRUITINGCorbeil-Essonnes, France, 91100, France
-
Centre Hospitalier Universitaire De Montpellier
RECRUITINGMontpellier, France, 34295, France
-
Hôpital Européen Marseille
RECRUITINGMarseille, 13003, France
-
Hôpital Lariboisière & Fernand-Widal
RECRUITINGParis, France
-
Hôpital Saint André -Centre Hospitalier Universitaire de Bordeaux
NOT_YET_RECRUITINGBordeaux, France, 33000, France
-
Hôpitaux Universitaires de Strasbourg - Nouvel Hôpital Civil
RECRUITINGStrasbourg, France
-
Isala Zwolle
RECRUITINGZwolle, Netherlands, 8025 AB, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.